PubMed Health⌕ Search

PubMed · 15756521

Dose to bone marrow using IMRT techniques in prostate cancer patients.

Abstract

PURPOSE: To investigate the dose distribution in active bone marrow of patients undergoing intensity-modulated radiotherapy (IMRT) for prostate cancer and compare it to the distribution in the same patients, if they had been treated using conformal plans, in order to develop criteria for optimization to minimize the estimated risk of secondary leukemia. PATIENTS AND METHODS: Mean bone marrow doses were calculated for ten patients with localized prostate cancer who underwent whole-pelvis IMRT and compared to three-dimensional conformal (3-D CRT) plans prepared for the same patients. Also for comparison, the IMRT and 3-D CRT plans were produced to simulate the treatment of the prostate gland only. To measure the dose to extrapelvic bone marrow, three thermoluminescent diode (TLD) chips were placed in the middle of the sternum region inside the Rando phantom. RESULTS: For both the pelvic and prostate-only volumes, the IMRT plans were superior to 3-D CRT plans in reducing the high dose volume to the rectum, the bladder and the small bowel while maintaining acceptable coverage of the planning target volume (PTV). For the pelvic treatment group the IMRT plans, compared to 3-D CRT, reduced the high dose volume (> 20 Gy) to os coxae, which is the main contributor of dose to pelvic bone marrow, but increased the middle dose volume (10-20 Gy). No statistically significant differences were observed for lower dose volumes (< 5 Gy). For the prostate-only treatment the IMRT plan increased the high dose volume and slightly decreased the low dose volume of pelvic bone marrow. However, for both treatments the leakage dose to extrapelvic sites was higher by a factor of 2 in IMRT plans. CONCLUSION: There are significant differences in the dose-volume histograms of bone marrow doses from 3-D CRT and from IMRT. Pronounced dose inhomogeneity reduces the risk of leukemia compared to homogeneous radiation exposure of the bone marrow. The mean bone marrow dose is therefore not a useful criterion to judge plan quality, since scattered low doses to distant sites may be more critical than the high dose volumes receiving > 10 Gy. The number of monitor units needed to deliver an IMRT plan affects leakage dose and their incorporation into planning constraints should be considered.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Eduard Gershkevitsh, Catharine H Clark, John Staffurth, David P Dearnaley, Klaus-Rüdiger Trott. 2005. Dose to bone marrow using IMRT techniques in prostate cancer patients.. https://doi.org/10.1007/s00066-005-1360-4

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Single cell mutational analysis of PIK3CA in circulating tumor cells and metastases in breast cancer reveals heterogeneity, discordance, and mutation persistence in cultured disseminated tumor cells from bone marrow.

BACKGROUND: Therapeutic decisions in cancer are generally guided by molecular biomarkers or, for some newer therapeutics, primary tumor genotype. However, because biomarkers or genotypes may change as new metastases emerge, circulating tumor cells (CTCs) from blood are being investigated for a role in guiding real-time drug selection during disease progression, expecting that CTCs will comprehensively represent the full spectrum of genomic changes in metastases. However, information is limited regarding mutational heterogeneity among CTCs and metastases in breast cancer as discerned by single cell analysis. The presence of disseminated tumor cells (DTCs) in bone marrow also carry prognostic significance in breast cancer, but with variability between CTC and DTC detection. Here we analyze a series of single tumor cells, CTCs, and DTCs for PIK3CA mutations and report CTC and corresponding metastatic genotypes. METHODS: We used the MagSweeper, an immunomagnetic separation device, to capture live single tumor cells from breast cancer patients' primary and metastatic tissues, blood, and bone marrow. Single cells were screened for mutations in exons 9 and 20 of the PIK3CA gene. Captured DTCs grown in cell culture were also sequenced for PIK3CA mutations. RESULTS: Among 242 individual tumor cells isolated from 17 patients and tested for mutations, 48 mutated tumor cells were identified in three patients. Single cell analyses revealed mutational heterogeneity among CTCs and tumor cells in tissues. In a patient followed serially, there was mutational discordance between CTCs, DTCs, and metastases, and among CTCs isolated at different time points. DTCs from this patient propagated in vitro contained a PIK3CA mutation, which was maintained despite morphological changes during 21 days of cell culture. CONCLUSIONS: Single cell analysis of CTCs can demonstrate genotypic heterogeneity, changes over time, and discordance from DTCs and distant metastases. We present a cautionary case showing that CTCs from any single blood draw do not always reflect metastatic genotype, and that CTC and DTC analyses may provide independent clinical information. Isolated DTCs remain viable and can be propagated in culture while maintaining their original mutational status, potentially serving as a future resource for investigating new drug therapies.

Bone Marrow↗

Trisomy 8 as sole cytogenetic abnormality in a case of chronic lymphocytic leukemia.

A 49-year-old man, who had been diagnosed with chronic lymphocytic leukemia (CLL) in 2002, had a normal karyotype in his bone marrow. Trisomy 8 was demonstrated in his peripheral blood in 2005. Fluorescence in situ hybridization using an LSI CEP 8 probe performed on the archival bone marrow specimen showed three hybridization signals in 40% of 200 interphase cells scored. This confirmed that the trisomy 8 abnormality was present in both the blood and bone marrow samples. Trisomy 8 as the sole chromosomal abnormality in CLL is a very rare finding. The prognostic significance of trisomy 8 in CLL remains to be seen.

Bone Marrow↗